Director dealing - REPLACEMENT

EDX Medical Group PLC
05 January 2024
 

The following amendment has been made to the 'Director dealing' announcement released on 04/01/2024 at 15:57 under RNS No 7059Y.

 

A previous version erroneously stated that following the share purchase, Professor Trevor Jones CBE owned 0.96% of the issued share capital. The correct figure owned by Professor Jones is 0.096% of the share capital.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

-------------------------------------------------------------------

 

 

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 

A blue hexagon with white x and blue x Description automatically generated with low confidence

 

Director dealing

5 January 2024

EDX Medical Group, plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, today announces that Professor Trevor Jones CBE, Senior Independent Director of the Company, purchased 150,000 ordinary shares in the Company on January 3, 2024, at 6.25 pence per share and 139,074 ordinary shares on January 4, 2024 at 7.35 pence per share. Following these purchases, Professor Jones owns 289,074 ordinary shares, representing his entire shareholding in the Company and 0.096% of the issued share capital.

 

The directors of the Company accept responsibility for the contents of this announcement.

 

Contacts:

EDX Medical plc


Dr Mike Hudson (Chief Executive Officer)

+44 (0)7812 345 301

 

 


Oberon Capital


Nick Lovering (Corporate Adviser)

Adam Pollock (Corporate Broking)

Mike Seabrook (Corporate Broking)

 

+44 (0)20 3179 5300



Media House International


Ramsay Smith

 

Gary McQueen

+44 (0)7788 414856

ramsay@mediahouse.co.uk

+ 44 (0)7834 694609

gary@mediahouse.co.uk

 

About EDX Medical Group plc

EDX Medical Group plc ("EDX Medical") develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases. The company is listed on the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Chris Evans, OBE, a very successful medical and life sciences entrepreneur with more than 35 years of experience building innovative life sciences companies.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to select personal treatment in a timely fashion.

Early disease detection and biologically-based personal treatment is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485 and key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

EDX Medical Group operates a molecular diagnostics and genomics laboratory in Cambridge, UK, a Point of Care test development group in Oxford (Hutano Diagnostics Ltd) and Torax Biosciences Ltd in Ireland.

Learn more: www.edxmedical.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings